Sofosbuvir/velpatasvir/voxilaprevir

Sofosbuvir/velpatasvir/voxilaprevir
Combination of
Sofosbuvir	NS5B RNA polymerase inhibitor
Velpatasvir	NS5A inhibitor
Voxilaprevir	NS3/4A protease inhibitor
Clinical data
Trade names	Vosevi
AHFS/Drugs.com	Monograph
MedlinePlus	a617037
License data	US DailyMed: Vosevi;
Pregnancy; category	AU: B1; ;
Routes of; administration	By mouth (tablets)
ATC code	J05AP56 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1190307-88-0 ; 1377049-84-7 ;
PubChem CID	129011857;
UNII	WJ6CA3ZU8B; KCU0C7RS7Z ;
KEGG	D10900;
Chemical and physical data
Formula	C111H135F5N17O26PS
Molar mass	2281.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1C2CN(C1C(=O)NC3(CC3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)C(NC(=O)OC5CC5CCCCC(C6=NC7=C(C=C(C=C7)OC)N=C6O2)(F)F)C(C)(C)C.CC1CCC(N1C(=O)C(C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)C8CC(CN8C(=O)C(C9=CC=CC=C9)NC(=O)OC)COC.CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3;
	InChI InChI=1S/C49H54N8O8.C40H52F4N6O9S.C22H29FN3O9P/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29;1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29;1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61);11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53);5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t27-,28-,38-,39-,41-,42+;20-,22-,23+,26-,27+,28+,30-,39-;14-,16+,18+,20+,22+,36-/m010/s1; Key:FMWRYUBVSONSCK-ZYTFCPLVSA-N;

Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.^[1] Vosevi was approved for medical use in the United States and in the European Union in July 2017.^[2]^[3] Vosevi is sold by Gilead Sciences.^{[citation needed]}

References

^ Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.
^ "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.
^ "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.

External links

"Sofosbuvir mixture with velpatasvir and voxilaprevir". Drug Information Portal. U.S. National Library of Medicine.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[Childs-Kean_2019-1] Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.

[fda-2] "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.

[3] "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.

[1]

[2]

[3]